Standard bioassays often fall short when evaluating T cell engagers due to their diverse mechanisms of actions (MOAs) and functional complexity. To generate meaningful preclinical data, ...

Nucleic acids (e.g., siRNA, mRNA and saRNA) can be designed and formulated to silence, express, and edit specific genes providing a flexible and powerful approach to preventing and treating diseases.

White Paper looks to support the successful development, validation and control of bioassays for successful drug development. The correct bioassay is integral to drug development, providing an ...

Since biological therapeutics are derived from living organisms, their manufacture and validation presents difficulties not encountered during traditional small molecule drug development. Despite the ...